Linked Life Data

17931196

Source:http://linkedlifedata.com/resource/pubmed/id/17931196

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17931196rdf:typepubmed:Citationlld:pubmed
pubmed-article:17931196lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:17931196lifeskim:mentionsumls-concept:C0008312lld:lifeskim
pubmed-article:17931196lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:17931196lifeskim:mentionsumls-concept:C0681890lld:lifeskim
pubmed-article:17931196lifeskim:mentionsumls-concept:C0443252lld:lifeskim
pubmed-article:17931196lifeskim:mentionsumls-concept:C2714264lld:lifeskim
pubmed-article:17931196pubmed:dateCreated2007-10-12lld:pubmed
pubmed-article:17931196pubmed:abstractTextBecause some of the autoreactive T-cell clones specific for human PDC-E2 cross-react to mimicry peptides having an EIExDK motif derived from nuclear antigens such as human gp210 and sp100, we studied the clinical significance of antinuclear antibodies (ANA) in primary biliary cirrhosis (PBC) patients registered to the National Hospital Organization Study Group for Liver Disease in Japan (NHOSLJ). We found that there are two different types of progression in PBC; one is a hepatic failure-type progression which is represented by positive anti-gp210 antibodies and the other is a portalhypertension-type progression which is represented by positive anticentromere antibodies. We discuss the predictive role of these ANA in the long-term outcome of PBC and the mechanisms by which two different PBC progression types occur based on molecular mimicry and aberrant expression of nuclear antigens.lld:pubmed
pubmed-article:17931196pubmed:languageenglld:pubmed
pubmed-article:17931196pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17931196pubmed:statusPubMed-not-MEDLINElld:pubmed
pubmed-article:17931196pubmed:monthOctlld:pubmed
pubmed-article:17931196pubmed:issn1386-6346lld:pubmed
pubmed-article:17931196pubmed:authorpubmed-author:DaikokuManabu...lld:pubmed
pubmed-article:17931196pubmed:authorpubmed-author:ItoMasahiroMlld:pubmed
pubmed-article:17931196pubmed:authorpubmed-author:IshibashiHiro...lld:pubmed
pubmed-article:17931196pubmed:authorpubmed-author:MigitaKiyoshi...lld:pubmed
pubmed-article:17931196pubmed:authorpubmed-author:YanoKojiKlld:pubmed
pubmed-article:17931196pubmed:authorpubmed-author:YatsuhashiHir...lld:pubmed
pubmed-article:17931196pubmed:authorpubmed-author:KondoHisayosh...lld:pubmed
pubmed-article:17931196pubmed:authorpubmed-author:NakamuraMinor...lld:pubmed
pubmed-article:17931196pubmed:authorpubmed-author:ShimodaShinji...lld:pubmed
pubmed-article:17931196pubmed:authorpubmed-author:OhataKazuyuki...lld:pubmed
pubmed-article:17931196pubmed:authorpubmed-author:KomoriAtsumas...lld:pubmed
pubmed-article:17931196pubmed:authorpubmed-author:AbiruSeigoSlld:pubmed
pubmed-article:17931196pubmed:authorpubmed-author:AibaYoshihiro...lld:pubmed
pubmed-article:17931196pubmed:authorpubmed-author:NagaokaShinya...lld:pubmed
pubmed-article:17931196pubmed:issnTypePrintlld:pubmed
pubmed-article:17931196pubmed:volume37 Suppl 3lld:pubmed
pubmed-article:17931196pubmed:ownerNLMlld:pubmed
pubmed-article:17931196pubmed:authorsCompleteYlld:pubmed
pubmed-article:17931196pubmed:paginationS412-9lld:pubmed
pubmed-article:17931196pubmed:year2007lld:pubmed
pubmed-article:17931196pubmed:articleTitlePredictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis.lld:pubmed
pubmed-article:17931196pubmed:affiliationNational Hospital Organization (NHO) Nagasaki Medical Center, Omura; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; and National Hospital Organization Study Group for Liver Disease in Japan (NHOSLJ), Fukuoka, Japan.lld:pubmed
pubmed-article:17931196pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17931196lld:pubmed